You just read:

OncoSec Provides Encouraging Interim Data from Ongoing KEYNOTE-890 Study of TAVO in Combination with KEYTRUDA® for the Treatment of Heavily Pretreated Chemotherapy/Radiotherapy Refractory Metastatic Triple Negative Breast Cancer

News provided by

OncoSec Medical Incorporated

May 22, 2019, 08:30 ET